Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer

Table 2 Hazard ratios for metastasis and death by Aspirin use and tumor PIK3CA mutation among women with metastatic breast cancer (N = 267)

	N	%	Metastasis			Death
	N	%	HR	95% CI	p-value	HR	95% CI	p-value
Age at Primary Dx
< 40	54	20.2	1.00	Reference		1.00	Reference
40–49	101	37.8	0.97	0.68–1.38	0.857	1.23	0.80–1.92	0.361
50–59	69	25.8	1.14	0.78–1.67	0.483	1.62	1.01–2.60	0.046
≥ 60	43	16.1	1.37	0.87–2.17	0.171	1.95	1.14–3.44	0.017
Stage at Primary Dx
1	62	23.2	1.00	Reference		1.00	Reference
2	131	49.1	1.41	1.01–1.94	0.040	1.34	0.89–1.95	0.149
3	59	22.1	1.53	1.04–2.20	0.026	1.59	1.01–2.45	0.041
Unknown	16	5.6	0.93	0.44–1.72	0.803	0.58	0.17–1.22	0.212
PR+	218	81.7	1.17	0.85–1.60	0.329	1.16	0.78–1.69	0.445
Grade
1	26	9.7	1.00	Reference		1.00	Reference
2	135	50.6	1.06	0.67–1.65	0.792	0.76	0.44–1.27	0.309
3	81	30.3	1.39	0.87–2.18	0.159	1.33	0.76–2.23	0.297
Unknown	25	9.4	0.51	0.28–0.93	0.025	0.44	0.21–0.93	0.027
Chemotherapy	214	80.1	0.98	0.70–1.36	0.886	1.15	0.77–1.72	0.497
PIK3CA mutated	97	36.3	0.73	0.55–0.95	0.022	0.86	0.61–1.18	0.376
Aspirin Use	54	20.2	0.91	0.64–1.27	0.592	1.04	0.68–1.54	0.855
Aspirin Use			p-interaction		0.006			0.026
Aspirin non-user
PIK3CA mutated	213	79.8	0.60	0.44–0.82	0.001	0.70	0.48–1.02	0.066
Aspirin user
PIK3CA mutated	54	20.2	1.57	0.86–2.84	0.139	1.75	0.88–3.49	0.11

ISSN: 1471-2407